Abstract 20P
Background
Biomarkers of response to IT are lacking in HGSC and PD-L1 expression failed to predict benefit in the randomized NeoPembrOv trial assessing peri-operative chemotherapy with or without pembrolizumab. We hypothesize that heterogeneity of samples site may impact the biomarker evaluation.
Methods
Biopsy of intra-abdominal metastases (M) or primary tubo-ovaries (TO) were obtained before any treatment. PD-L1 expression (Ventana SP263) (N = 85), multiplex immunofluorescence (mIF) (N = 64) and RNAseq data (N = 57) were assessed. Differentially expressed genes (DEG) and gene set enrichment analysis (GSEA) were obtained with DESeq2. Survival was analyzed with Cox models.
Results
No major difference of immune infiltration was seen between TO and M samples (mIF data). TO were enriched in tumor cells and TPS ≥ 1 samples (Table). In M, CPS ≥1 was predictive of better PFS in the pembrolizumab arm as compared to chemotherapy alone arm (HR interaction = 0.26 CI 95% 0.07-0.93 P = 0.034). No significant benefit was seen with TPS and IC, nor in TO. Intra-tumoral CD8 T cell (iCD8) density was higher in the IC, TPS and CPS ≥ 1 subgroups and was correlated with PD-L1 expression in M but not in TO (Table). Higher iCD8 T cells density (P = 0.03) and an enrichment of immune hallmarks (Interferon alpha and gamma, allograft rejection, inflammatory response, P < 0.05) was seen in CPS ≥ 1 M vs CPS ≥ 1 TO. On the other hand, CPS ≥ 1 TO samples were enriched in proliferative pathways (MYC and E2F target, G2M checkpoint, oxidative phosphorylation, P < 0.05) compared to CPS ≥ 1 M. Table: 20P
Tubo-ovary n=29 | Metastases, n=56 | P-value | |
PD-L1 expression | |||
Combined positive score (CPS) ≥ 1 | 79% | 60% | 0.08 |
Tumor positive score (TPS) ≥ 1 | 66% | 34% | 0.01 |
Immune cell score (IC) ≥ 1 | 45% | 53% | 0.48 |
Correlation between PD-L1 and iCD8 T cells (spearman ρ) | |||
CPS | ρ = 0.27 P = 0.2 | ρ = 0.53 P < 0.001 | |
TPS | ρ = 0.34 P = 0.1 | ρ = 0.50 P < 0.001 | |
IC | ρ = 0.02 P = 0.9 | ρ = 0.49 P < 0.001 |
Conclusions
CPS ≥ 1 in M, but not in primitive tumor, is associated with pembrolizumab benefit, consistent with the increase of iCD8 T cells in PD-L1 positive M. This indicates that the site of tumor sampling influence prediction of potential efficacy of PDL1 inhibitors in HGSC.
Clinical trial identification
NCT03275506.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Leheurteur: Financial Interests, Personal, Advisory Board: MSD. F. Selle: Financial Interests, Personal, Invited Speaker: AstraZeneca, MSD, GSK/Tesaro, Eisai; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, GSK/Tesaro. C. Sotiriou: Financial Interests, Institutional, Advisory Board: Astellas, Vertex, Seattle Genetics, Amgen, INC, Merck & Co; Financial Interests, Personal, Advisory Board: Cepheid, Puma; Financial Interests, Personal, Invited Speaker: Eisai, Prime oncology, Teva; Financial Interests, Institutional, Other, Travel: Roche; Financial Interests, Institutional, Other, Internal speaker: Genentech; Financial Interests, Personal, Other, Regional speaker: Pfizer; Financial Interests, Institutional, Invited Speaker: Exact Sciences. I.L. Ray-Coquard: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, Mersana, Deciphera, Amgen, Oxnea, Merck Sereno, Agenus, Novartis, Macrogenics, Clovis, EQRX, Adaptimmune, Eisai, SUTRO, BMS, Adaptimmune, Daiichi Sankyo; Financial Interests, Institutional, Other, COLIBRI translational research: BMS; Financial Interests, Institutional, Advisory Board, translational research NEOPREMBROV trial: MSD; Non-Financial Interests, Personal, Principal Investigator: PAOLA1; Non-Financial Interests, Personal, Other, President: GINECO. O. Le Saux: Financial Interests, Personal, Advisory Board: Novartis, MSD, GSK; Financial Interests, Personal, Invited Speaker: Lilly, AstraZeneca, Clovis; Financial Interests, Institutional, Trial Chair: Novartis, Hospira-Pfizer foundation, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
170P - Targeting myeloid cells in non-small cell lung cancer and hepatocellular carcinoma: a window-of-opportunity trial of nivolumab with BMS-813160 (CCR2/5i) or BMS-986253 (anti-IL8)
Presenter: Nicholas Venturini
Session: Poster Display
171P - Immune landscape and CLEVER-1 expression in hepatoblastoma
Presenter: Ville Väyrynen
Session: Poster Display
172P - PLCE1 stabilizes ENO1 to enhance glycolysis in esophageal squamous cell carcinoma (ESCC) and induces an immune-suppressive tumor microenvironment
Presenter: Ju Yang
Session: Poster Display
173P - Depleting resident peritoneal macrophages is an effective treatment for peritoneal metastasized colorectal cancer
Presenter: Job Saris
Session: Poster Display
174P - Targeting SPHK1 in macrophages suppresses liver metastasis of colorectal cancer and decouples anti-tumor immunity from immunotherapy toxicity
Presenter: Yizhi Zhan
Session: Poster Display
175P - MicroRNA-548c: An Immune-Activator microRNA at the Tumor Microenvironment and Immune Milieu of Breast Cancer
Presenter: Alyaa Dawoud
Session: Poster Display
176P - Multiplex-immunoflourescence spatial patterns to predict triple-negative breast cancer molecular subtypes in the IMMUcan study
Presenter: Andrea Joaquin Garcia
Session: Poster Display
177P - The Immune-microenvironment Confers Chemoresistance in Breast cancer through activation of VEGFR2/STAT3/BIRC5 signaling
Presenter: Bhawna Deswal
Session: Poster Display
178P - Dynamics of breast cancer T cell repertoire during neoadjuvant chemotherapy / immunotherapy.
Presenter: Charlotte Birchall
Session: Poster Display
179P - Integrating multiplex immunofluorescence with gene expression data in the IMMUcan HER2-positive breast cancer cohort
Presenter: Mattia Rediti
Session: Poster Display